Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (388)
- Scheduling (national classification system) (171)
- Safety monitoring and information (27)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Clinical trials (6)
- Medicinal cannabis hub (6)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
33 result(s) found, displaying 26 to 33
-
Corporate reportsThis report describes the first 12 months of the mandatory reporting scheme
-
Corporate reportsNew chemical entities registered in 2017 in Australia.
-
Scheduling decisions (final)Final decisions for substances referred to the ACMS, ACCS/ACMS, ACCS November 2017 meetings, and delegate only decisions on agricultural and veterinary chemicals and NCEs.
-
Corporate reportsReport detailing prescription medicines registrations for 2017
-
Corporate reportsNew generic medicines and biosimilar medicines registered in 2017
-
Scheduling decisions (final)Final decisions for medicines and chemicals referred to March 2017 scheduling meetings (ACMS #20, ACCS #19 and Joint ACMS-ACCS #15) and NCEs.
-
Corporate reportsSummary of generic and biosimilar prescription medicines registered in Australia in 2016
-
Corporate reportsEach year, approximately 40 new prescription medicines containing new active substances are registered.